Basuli Debargha, Parekh Rohan Umesh, White Acacia, Thayyil Abdullah, Sriramula Srinivas
Department of Pharmacology and Toxicology, Brody School of Medicine at East Carolina University, Greenville, NC, United States.
Department of Nephrology and Hypertension, Brody School of Medicine at East Carolina University, Greenville, NC, United States.
Front Med (Lausanne). 2022 Jan 18;8:780834. doi: 10.3389/fmed.2021.780834. eCollection 2021.
Despite many readily available therapies, hypertensive kidney disease remains the second most prevalent cause of end-stage renal disease after diabetes, and continues to burden patient populations and escalate morbidity and mortality rates. Kinin B1 receptor (B1R) activation has been shown to have a role in the development of hypertension, one of the major etiologies for chronic kidney disease. However, the role of B1R in hypertension induced renal injury and remodeling remains unexplored. Using a DOCA-salt-induced hypertensive mouse model, we investigated whether B1R deficiency reduces hypertensive renal injury and fibrosis. To further recognize the translational role of B1R, we examined the expression of B1R and its correlation with collagen deposition in renal biopsies from control and hypertensive kidney disease patients. Our data indicates that renal B1R expression was upregulated in the kidneys of DOCA-salt hypertensive mice. Genetic ablation of B1R protected the mice from DOCA-salt-induced renal injury and fibrosis by preventing inflammation and oxidative stress in the kidney. Cultured human proximal tubular epithelial cells expressed B1R and stimulation of B1R with an agonist resulted in increased oxidative stress. In human kidney biopsy samples, we found that the B1R immunoreactivity was not only significantly increased in hypertensive patients compared to normotensive patients, but also there is a positive correlation between B1R expression and renal fibrosis levels. Taken together, our results identify a critical role of B1R in the development of inflammation and fibrosis of the kidney in hypertension.
尽管有许多现成的治疗方法,但高血压肾病仍然是仅次于糖尿病的第二大常见终末期肾病病因,并且继续给患者群体带来负担,导致发病率和死亡率不断上升。激肽B1受体(B1R)激活已被证明在高血压的发展中起作用,高血压是慢性肾病的主要病因之一。然而,B1R在高血压诱导的肾损伤和重塑中的作用仍未得到探索。我们使用去氧皮质酮盐诱导的高血压小鼠模型,研究了B1R缺陷是否能减轻高血压肾损伤和纤维化。为了进一步认识B1R的转化作用,我们检测了对照和高血压肾病患者肾活检中B1R的表达及其与胶原蛋白沉积的相关性。我们的数据表明,去氧皮质酮盐高血压小鼠肾脏中的肾B1R表达上调。B1R基因敲除通过预防肾脏炎症和氧化应激,保护小鼠免受去氧皮质酮盐诱导的肾损伤和纤维化。培养的人近端肾小管上皮细胞表达B1R,用激动剂刺激B1R会导致氧化应激增加。在人肾活检样本中,我们发现与血压正常的患者相比,高血压患者的B1R免疫反应性不仅显著增加,而且B1R表达与肾纤维化水平之间存在正相关。综上所述,我们的结果确定了B1R在高血压肾脏炎症和纤维化发展中的关键作用。